Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Bleicher

Endocrinology, Diabetes & Metabolism North Miami Beach, FL Doctor of Osteopathy

NPI 1053656561 CMS profile 274512

1380 Ne Miami Gardens Dr Ste 155, North Miami Beach, FL 33179

Open in the dashboard

General payments

$5,126

248 records reported · program years 2019–2025

Research payments

$3,180

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,275,208 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Jeremy Bleicher of North Miami Beach, FL is reported in the CMS Open Payments database as having received $5,126 across 248 general payments and $3,180 in research payments paid to them. Separately, studies naming them as principal investigator received $2,275,208 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 75th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $618 28
2024 General $627 25
2024 Research $3,180 1
2023 General $795 37
2022 General $468 27
2021 General $630 27
2020 General $491 29
2019 General $1,497 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Bleicher
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Jeremy Bleicher were reported at $618. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Jeremy Bleicher Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $1,497 $494 $123–$2,253 $163
2020 $491 $335 $85–$1,841 $114
2021 $630 $398 $88–$1,981 $132
2022 $468 $364 $88–$1,568 $149
2023 $795 $420 $113–$1,614 $160
2024 $627 $440 $121–$1,646 $164
2025 $618 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $867 40 payments
  2. Insulet Corporation $636 25 payments
  3. Novo Nordisk Inc $504 26 payments
  4. Sanofi-Aventis U.S. LLC $500 21 payments
  5. Abbott Laboratories $410 25 payments
  6. Mannkind Corporation $336 18 payments
  7. AbbVie, Inc. $263 19 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $255 12 payments
  9. Valeritas, Inc. $156 4 payments
  10. Janssen Pharmaceuticals, Inc $140 15 payments
  11. Other $1,059 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,112 246 payments
  2. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. Omnipod $546 20 payments
  2. Ozempic $369 20 payments
  3. AFREZZA $285 15 payments
  4. FreeStyle Libre 2 $274 20 payments
  5. JARDIANCE $255 12 payments
  6. MOUNJARO $247 12 payments
  7. RYBELSUS $212 10 payments
  8. LYUMJEV $210 8 payments
  9. TRULICITY $176 10 payments
  10. TOUJEO $169 5 payments
  11. Other $3,182 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Becton, Dickinson and Company $3,180 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

2,044

Median for Endocrinology: 1,959

Drug cost

$556,409

Median for Endocrinology: $890,201

Branded share of claims

68.6%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 132 $136,146
Mounjaro Tirzepatide Brand 46 $52,005
Trulicity Dulaglutide Brand 29 $43,545
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 72 $41,200
Jardiance Empagliflozin Brand 22 $35,313
Rybelsus Semaglutide Brand 28 $30,032
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 28 $22,943
Farxiga Dapagliflozin Propanediol Brand 23 $20,090
Tresiba Flextouch U-200 Insulin Degludec Brand 25 $19,201
Tresiba Flextouch U-100 Insulin Degludec Brand 44 $18,831

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$63,998

Medicare's payments for the services billed

Medicare patients

205

Average age 72

Services billed

637

98 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 68%
Heart failure 59%
Ischemic heart disease 59%
Depression 52%
Arthritis 52%
Alzheimer's or dementia 50%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $66
$66 46 —
RYBELSUS
  • Novo Nordisk Inc $60
$60 28 —
Ozempic
  • Novo Nordisk Inc $51
$51 132 —
AFREZZA
  • Mannkind Corporation $48
$48 — —
Korlym
  • Corcept Therapeutics $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record